Results 141 to 150 of about 7,770 (204)

BIOSIMILARS IN ONCOLOGY – PART I: THE PRINCIPLES OF BIOSIMILARS

Belgian Journal of Medical Oncology, 2020
Moorkens, Evelien, Vandenplas, Yannick, barcina, Teresa, Barbier, Liese, Vulto, Arnold   +4 more
openaire   +2 more sources

Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Zhou Y, Zhan Z, Wang Z, Liu C.
europepmc   +1 more source

Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars. [PDF]

J Am Soc Mass Spectrom
Beaumal C, Srzentić K, Carillo S, Bones J.   +3 more
europepmc   +1 more source

Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization: A Scoping Review.

JAMA Health Forum
Watanabe JH, Strand MW, Walvekar M, Alfonso-Cristancho R.   +3 more
europepmc   +1 more source

The FDA's adoption of Bayesian methodology: transforming clinical trial justification from biosimilars to broader drug development. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]

Clin Exp Med
Shakibaei F, Malekshahi S, Heidari N, Heidari A.   +3 more
europepmc   +1 more source

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. [PDF]

J Clin Med
Shehab M, Almajdi A, Abdullah I, Alrashed F.   +3 more
europepmc   +1 more source

Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study. [PDF]

Healthcare (Basel)
Alqahtani S, Almanasef M.
europepmc   +1 more source

Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses. [PDF]

Ann Clin Epidemiol
Morita T, Sasabuchi Y, Yasunaga H.
europepmc   +1 more source